Wall Street analysts expect that STRATA Skin Sciences Inc (NASDAQ:SSKN) will post $8.11 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for STRATA Skin Sciences’ earnings. The lowest sales estimate is $7.62 million and the highest is $8.40 million. STRATA Skin Sciences posted sales of $8.60 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 5.7%. The company is scheduled to report its next quarterly earnings report on Monday, April 1st.

On average, analysts expect that STRATA Skin Sciences will report full-year sales of $29.90 million for the current year, with estimates ranging from $29.51 million to $30.20 million. For the next year, analysts forecast that the firm will report sales of $34.54 million, with estimates ranging from $34.42 million to $34.70 million. Zacks’ sales averages are an average based on a survey of research firms that cover STRATA Skin Sciences.

STRATA Skin Sciences (NASDAQ:SSKN) last released its quarterly earnings data on Tuesday, November 13th. The medical device company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.03. The business had revenue of $7.89 million for the quarter, compared to analyst estimates of $7.64 million. STRATA Skin Sciences had a negative return on equity of 18.83% and a negative net margin of 18.33%.

SSKN has been the subject of a number of research analyst reports. Zacks Investment Research upgraded STRATA Skin Sciences from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a report on Friday, November 16th. Northland Securities initiated coverage on STRATA Skin Sciences in a report on Monday, December 10th. They issued an “outperform” rating and a $7.00 target price for the company. Finally, HC Wainwright set a $5.00 target price on STRATA Skin Sciences and gave the stock a “buy” rating in a report on Wednesday, November 14th. Five analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus price target of $4.92.

NASDAQ:SSKN traded down $0.02 during trading hours on Wednesday, hitting $2.90. The company’s stock had a trading volume of 32,444 shares, compared to its average volume of 34,999. STRATA Skin Sciences has a twelve month low of $1.09 and a twelve month high of $3.88. The firm has a market capitalization of $86.83 million, a PE ratio of 1.47 and a beta of 0.97. The company has a quick ratio of 4.03, a current ratio of 4.54 and a debt-to-equity ratio of 0.22.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SSKN. Vanguard Group Inc increased its holdings in shares of STRATA Skin Sciences by 3,605.7% during the third quarter. Vanguard Group Inc now owns 593,357 shares of the medical device company’s stock valued at $2,100,000 after acquiring an additional 577,345 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of STRATA Skin Sciences by 3,605.7% during the third quarter. Vanguard Group Inc. now owns 593,357 shares of the medical device company’s stock valued at $2,100,000 after acquiring an additional 577,345 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of STRATA Skin Sciences by 154.0% during the third quarter. Renaissance Technologies LLC now owns 745,583 shares of the medical device company’s stock valued at $2,639,000 after acquiring an additional 452,084 shares in the last quarter. EAM Investors LLC bought a new stake in shares of STRATA Skin Sciences during the third quarter valued at approximately $830,000. Finally, Macquarie Group Ltd. increased its holdings in shares of STRATA Skin Sciences by 89.7% during the second quarter. Macquarie Group Ltd. now owns 134,033 shares of the medical device company’s stock valued at $275,000 after acquiring an additional 63,393 shares in the last quarter. Hedge funds and other institutional investors own 26.94% of the company’s stock.

About STRATA Skin Sciences

STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.

Further Reading: Outstanding Shares, Buying and Selling Stocks

Get a free copy of the Zacks research report on STRATA Skin Sciences (SSKN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.